SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CVTX - CV Therapeutics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (354)11/11/2008 2:51:05 PM
From: scaram(o)uche  Read Replies (1) of 411
 
Well..... the "one less pill" argument is interesting. If cvtx were expected to steal first-line angina treatment, market cap would be > $15B.

Another way of looking at it..... new-onset patients who choose ranexa will be taking 14 pills a week, period.

There are plenty of hooks.... FDA has handed out a nice label for angina, and I suspect that there will be significant off-label use for AF.

Given safety to date, seems like there's tons of room for growth, short of ML's "game changer"...... lots of interesting observations, clinical and preclinical, that the company can't discuss. I feel that it will be an EXCITING profession, near-term detailing for ranexa.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News